279 related articles for article (PubMed ID: 29128670)
1. Synchronous immune alterations mirror clinical response during allergen immunotherapy.
Renand A; Shamji MH; Harris KM; Qin T; Wambre E; Scadding GW; Wurtzen PA; Till SJ; Togias A; Nepom GT; Kwok WW; Durham SR
J Allergy Clin Immunol; 2018 May; 141(5):1750-1760.e1. PubMed ID: 29128670
[TBL] [Abstract][Full Text] [Related]
2. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
3. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
[TBL] [Abstract][Full Text] [Related]
4. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
5. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
6. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R
J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.
James LK; Shamji MH; Walker SM; Wilson DR; Wachholz PA; Francis JN; Jacobson MR; Kimber I; Till SJ; Durham SR
J Allergy Clin Immunol; 2011 Feb; 127(2):509-516.e1-5. PubMed ID: 21281875
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
9. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
10. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
[TBL] [Abstract][Full Text] [Related]
11. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
12. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
14. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
15. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
17. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
[TBL] [Abstract][Full Text] [Related]
18. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
19. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
